mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats

Shunsaku Nakagawa, Satohiro Masuda, Kumiko Nishihara, Ken-ichi Inui *

Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, Japan

ABSTRACT

Responsible factors in progressive tubular dysfunction in chronic renal failure have not been fully identified. In the present study, we hypothesized that the mammalian target of rapamycin, mTOR, was a key molecule in the degenerative and progressive tubular damage in chronic renal failure. Everolimus, an mTOR inhibitor, was administered for 14 days in 5/6 nephrectomized (Nx) rats at 2 and 8 weeks after renal ablation. Marked activation of the mTOR pathway was found at glomeruli and proximal tubules in remnant kidneys of Nx rats. The reduced expression levels of the phosphorylated S6 indicated the satisfactory pharmacological effects of treatment with everolimus for 14 days. Everolimus suppressed the accumulation of smooth muscle alpha actin, infiltration of macrophages and expression of kidney injury molecule-1 in the proximal tubules. In addition, everolimus-treatment restored the tubular reabsorption of albumin, and had a restorative effect on the expression levels of membrane transporters in the polarized proximal tubular epithelium, when its administration was started at 8 weeks after Nx. These results indicate that the constitutively activated mTOR pathway in proximal tubules has an important role in the progressive tubular dysfunction, and that mTOR inhibitors have renoprotective effects to improve the proximal tubular functions in end-stage renal disease.

© 2009 Elsevier Inc. All rights reserved.

1. Introduction

In chronic renal failure (CRF), the irreversible and progressive loss of nephrons ultimately results in glomerular sclerosis, tubular atrophy and further reductions in nephron numbers [1,2]. These physiological changes produce a complex series of adverse effects that eventuate in progressive renal injury and a severe decline in function. We have demonstrated expressional and functional alterations of drug transporters in the proximal tubules of 5/6 nephrectomized (Nx) rats, a model of CRF [3–6]. Furthermore, levels of tubular transporters that play important roles in the handling of nutrients and electrolytes were also decreased in Nx rats [7,8]. Therefore, a decline in tubular functions causes the accumulation of uremic toxin, metabolites and xenobiotics and increases renal dysfunction and systemic toxicity [9,10]. Consequently, it is important to understand the molecular mechanisms behind in CRF and improve therapeutic approaches for the progressive tubular dysfunction.

Mammalian target of rapamycin, mTOR, is a serine/threonine kinase that regulates a variety of cellular processes including growth, proliferation and metabolism [11–13]. mTOR inhibitors such as rapamycin (sirolimus) and everolimus are generally used as immunosuppressants to prevent immunological reactions after organ transplantation. Everolimus is an immunosuppressive macrolide derived from rapamycin. Although they exhibit slightly different pharmacokinetic properties, both everolimus and rapamycin exert their effects by the same mechanism [12]. Each drug binds to the intracellular cofactor FK506-binding protein (FKBP12) to form a complex, which then binds to mTOR interfering signal transduction to its downstream effectors.

Recently, it was reported that rapamycin reduced interstitial fibrosis and glomerular sclerosis after kidney transplantation in patients with chronic allograft nephropathy [14,15]. In addition, a causal link between the activation of the mTOR pathway and the progression of polycystic kidney disease or diabetic nephropathy was reported [16–18]. However, it is still unclear whether the mTOR pathway associates with tubular functions such as the reabsorption of nutrients and secretion of xenobiotics and metabolites.

Previous studies suggest the relationship between the mTOR pathway and the progression of CRF. Diekmann et al. [19] reported that rapamycin abolished the progression of proteinuria and structural damage when administered from the 6th week after nephrectomy in CRF rats, while Vogelbacher et al. [20] reported that everolimus induced renal deterioration and proteinuria when given from the 3rd day after nephrectomy. These findings encouraged us to examine the pharmacological effects of everolimus in Nx rats,

* Corresponding author. Tel.: +81 75 751 3577; fax: +81 75 751 4207.
  E-mail address: inui@kuhp.kyoto-u.ac.jp (K.-i. Inui).

focusing on tubular functions, by subcutaneously administration of everolimus at 2 and 8 weeks after renal ablation. Our findings revealed the constitutive activation of the mTOR pathway at proximal tubules in the remnant kidneys, and the therapeutic effects of everolimus for the progression of tubular dysfunction in CRF.

2. Materials and methods

2.1. Animals

The experimental design is shown in Fig. 1. For ablation of the renal mass, male Wistar/ST rats (180–200 g) were anesthetized with sodium pentobarbital (50 mg/kg) and the kidneys were exposed under aseptic conditions via a ventral abdominal incision. The right kidney was removed, the posterior and anterior apical segmental branches of the left renal artery were individually ligated, and the abdominal incision was closed with 4-0 silk sutures [3,4]. After surgery, animals were allowed to recover from anesthesia and surgery in cages with free access to water and standard rat chow. To investigate the effects of the mTOR inhibitor everolimus on the progression of CRF, rats were administered everolimus (LC Laboratories, Woburn, MA; 2 mg/kg body weight, E(+)) or vehicle (E(−)) subcutaneously for 14 days. The administration of everolimus was initiated at 2 and 8 weeks after surgery. After the 14-day administration, the subsequent experiments were carried out. The concentration of everolimus in whole blood samples was measured using LC/MS/MS [21]. The experiments with animals were performed in accordance with the *Guidelines for Animal Experiments of Kyoto University*. All protocols were previously approved by the Animal Research Committee, Graduate School of Medicine, Kyoto University.

2.2. Renal function and histology

Rats were maintained in metabolic cages for 24 h to collect 24-h urine samples. The animals were fed normal pellet food ad libitum, and given water freely in metabolic cages. Then, rats were anesthetized with an intraperitoneal administration of 50 mg/kg sodium pentobarbital to collect plasma and kidneys. Urinary albumin was assessed using an enzyme-linked immunosorbent assay (ELISA) kit (Nephrat II) (Exocell, Inc., Philadelphia, PA). The levels of creatinine in plasma and urine were determined with the Jaffé reaction. The BUN concentration was determined by the urease/indophenol method. For measurements, we used assay kits from Wako Pure Chemical Industries (Osaka, Japan). Kidneys were fixed in ethyl Carnoy's solution and stained with periodic acid-Schiff (PAS) reagent by Sapporo General Pathology Laboratory Co., Ltd. (Hokkaido, Japan). The glomerular diameter and inside diameter of tubules were determined as the mean value from 20 glomeruli and 40 proximal tubules, respectively.

2.3. Western blot analysis

The rat whole kidney was homogenized in lysis buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 10 mM NaF, 1 mM $Na_4P_2O_7$, 100 mM Na_3VO_4, 1% NP-40 and 1% protease inhibitor cocktail (Nacalai Tesque, Kyoto, Japan)). The tissue lysate was clarified by centrifugation, and protein concentrations were determined with the Bradford protein assay (Bio-Rad Laboratories, Hercules, CA). The crude membrane fractions of the rat kidney were prepared as described [22]. The kidney lysate was used for the analyze the protein levels of phosphorylated Akt (p-Akt), mTOR (p-mTOR), S6 kinase (p-S6 kinase), ribosomal protein S6 (p-S6), kidney injury molecule-1 (Kim-1), smooth muscle alpha actin (alpha-SMA), beta-actin and GAPDH. The membrane fraction was used for Na^+/D-glucose cotransporter (SGLT) 1, Na^+/H^+ exchanger (NHE) 3, H^+/peptide cotransporter (PEPT) 1, PEPT2, organic cation transporter (OCT) 1, OCT2 organic anion transporter (OAT) 1, OAT3, H^+/organic cation antiporter (MATE, multidrug and toxin extrusion) 1, P-glycoprotein (P-gp) and the Na^+/K^+-ATPase alpha1 subunit. Equal amount of the lysate or membrane fraction was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA). The blots were blocked, washed, and incubated with the primary antibodies (for total Akt, p-Akt, total mTOR, p-mTOR, p-S6K, total S6, p-S6 (Cell Signaling Technology, Danvers, MA), GAPDH (Santa Cruz Biotechnology, Avenue, CA), alpha-SMA, beta-actin (Sigma), Kim-1 (generated in our laboratory referring to the report by Ichimura et al. [23], Fig. 2),

Fig. 1. Experimental design. Rats were administered everolimus (2 mg/kg body weight, E(+)) or vehicle E(−)) subcutaneously for 14 days. The trough concentration of everolimus at the 15th day was 18.4 ± 1.2 ng/mL. The administration of everolimus was initiated at 2 and 8 weeks after 5/6 nephrectomy. Open triangle, initiation of administration; closed triangle, sample collection; open bar, administration of vehicle; closed bar, administration of everolimus.

Fig. 2. Polyclonal antibody against Kim-1. Polyclonal antibody was raised against the synthetic peptide corresponding to the R9 region of rat Kim-1 (HPRAEDNIYIIEDRSRG) [23]. Tissue lysates (50 μg) from normal kidney (lanes 1 and 3) or Nx rat kidneys at 10 weeks after surgery (lanes 2 and 4) were separated by SDS-PAGE and blotted onto PVDF membranes. Antibody specific for Kim-1 (lanes 1 and 2) or antibody preabsorbed with the synthetic antigen peptide (10 μg/mL) (lanes 3 and 4) were used as primary antibody. Kim-1 protein was up-regulated in the Nx rat kidneys. The preabsorption of antibody with corresponding antigen peptide abolished these positive bands, showing the presence of Kim-1 protein in the rat kidney. Arrows indicate the position of the Kim-1 specific bands.

SGLT1, NHE3, Na$^+$/K$^+$-ATPase alpha1 subunit (Millipore), PEPT1 [24], PEPT2 [25], OCT1 [26], OCT2 [27], OAT1, OAT3 [4], MATE1 [6] and P-gp (monoclonal antibody C219 [28])) overnight at 4 °C. The bound antibody was detected on X-ray film by enhanced chemiluminescence (ECL) with horseradish peroxidase-conjugated secondary antibodies and cyclic diacylhydrazides (GE Healthcare Bio-Sciences Corp., Piscataway, NJ). Beta-actin, GAPDH and the Na$^+$/K$^+$-ATPase alpha1 subunit were examined as controls. The relative densities of the bands in each lane were determined using NIH Image J 1.39 (National Institute of Health, Bethesda, MD, USA).

2.4. Immunofluorescence analysis

Rats at 15th days after the daily administration of everolimus or vehicle from 2 or 8 weeks after surgery were used. After perfusion with 4% paraformaldehyde in PBS (Wako), and the kidneys were embedded in Tissue-Tek® O.C.T. compound (Sakura Finetechnical, Tokyo, Japan) and frozen rapidly in liquid nitrogen. Sections (6 μm thick) were cut and covered with 5% BSA in PBS containing 0.3% Triton X-100. The covered sections were incubated for overnight at 4 °C with the primary antibodies (1:200 dilution) specific for p-mTOR, p-S6, alpha-SMA, ED1 and rat Kim-1 (R&D Systems, Minneapolis, MN), washing three times, and incubated with secondary antibodies (Cy3-labeled donkey anti-rabbit IgG (ALTAG Laboratory, San Francisco, CA) for p-mTOR and p-S6, Alexa 546-labeled donkey anti-goat IgG (Invitrogen Japan K.K., Tokyo, Japan) for rat Kim-1, Alexa 546-labeled goat anti-mouse IgG (Invitrogen) for ED1 and alpha-SMA), Alexa 488-Phalloidin (Invitrogen), and DAPI (Wako, Osaka, Japan) at 37 °C for 60 min. These sections were examined under a fluorescence microscope BZ-9000 (KEYENCE, Osaka, Japan). Signals for secondary antibodies, Alexa 488-Phalloidin and DAPI were captured, and the images of each color signals in the same section were merged.

2.5. Infusion experiment

Renal distribution of fluorescein isothiocyanate-conjugated human albumin (FITC-albumin; Sigma, Deisenhofen, Germany) was measured in rats at 15th days after the daily administration of everolimus or vehicle from 8 weeks after surgery. Rats were anesthetized with an intraperitoneal administration of 50 mg/kg sodium pentobarbital, and catheterized at right femoral vein for the administration of FITC-albumin. Urine was collected from the urinary bladder catheterized with the tubing (Intramedic PE-50, Becton Dickinson and Co., Parsippany, NJ). Thereafter, FITC-albumin (5 mg/kg) was administered as a bolus via the femoral vein. Urine samples were collected during a 20-min period, and then, the kidneys were harvested. The FITC-albumin concentrations in urine were determined with an ELISA kit (AssayMax Human Albumin ELISA Kit) (ASSAYPRO, Triad South Drive St. Charles, MO). Fixed kidneys were frozen rapidly in liquid nitrogen. Sections (6 μm thick) were cut and incubated with Alexa 594-Phalloidin (Invitrogen) at 37 °C for 30 min. Signals for FITC-albumin or Alexa 594-Phalloidin were captured with a BZ-9000. Area of signals for FITC-albumin was calculated in three independent fields of renal cortex from six independent rats. The images of FITC-albumin and Alexa 594-Phalloidin in the same section were merged.

2.6. Statistical analysis

Data are expressed as means ± SEM. Data were statistically analyzed using the unpaired Student's t-test or multiple comparisons with Bonferroni's two-tailed test after a one-way ANOVA. Probability values of less than 0.05 were considered statistically significant.

Statistical analysis was performed using Prism Version 4.0 software (GraphPad, San Diego, CA).

3. Results

3.1. Protein expression of phosphorylated Akt, mTOR, S6 kinase and S6

The phosphatidylinositol 3-kinases (PI3K)/Akt pathway is an upstream regulator of mTOR, and the activation of mTOR leads to the phosphorylation of downstream targets, such as S6 kinase and S6 [11,12]. After the 14 days' subcutaneous administration of everolimus (Fig. 1), the protein levels of p-Akt, p-mTOR, p-S6 kinase, p-S6 in the Nx rat kidneys were examined (Fig. 3). Although slight variations in the levels of total Akt, mTOR and S6 were observed, the levels of p-Akt, p-S6 kinase and p-S6 as well as p-mTOR were markedly increased in Nx rat kidneys compared to the control rat kidney (Fig. 3, Control vs. 4 weeks E(−) or 10 weeks E(−)). The treatment with everolimus markedly decreased the levels of p-S6 kinase and p-S6 (Fig. 3, 4 weeks E(−) vs. E(+), 10 weeks E(−) vs. E(+)). In addition, the levels of p-Akt and p-mTOR tended to decrease on treatment with everolimus, when the administration was started at 8 weeks after surgery (Fig. 3, 10 weeks E(−) vs. E(+)).

An immunofluorescence analysis revealed extensive staining of p-mTOR and p-S6 in the renal cortex (Fig. 4A–F). In the control rat kidneys, the signals for p-mTOR were predominantly observed in distal tubules (Fig. 4A, arrowhead), while the signals for p-S6 were observed in proximal tubules (Fig. 4B, arrow) as well as distal tubules (Fig. 4B, arrowhead). In the remnant kidneys, the staining


Fig. 3. Activation of the mTOR pathway in Nx rat kidneys. Four weeks and 10 weeks represent groups in which a 14-day subcutaneous administration of everolimus (2 mg/kg/day) or vehicle was initiated at 2 and 8 weeks after surgery, respectively. Tissue lysate (50 μg) from total kidney was separated by SDS-PAGE and blotted onto PVDF membranes. Antisera specific for total Akt, p-Akt, total mTOR, p-mTOR, p-S6 kinase total S6, p-S6 and GAPDH (1:1000–4000 dilution) were used as primary antibody. Control, lysate obtained from normal kidney; E(−), Nx rats administered vehicle; E(+), Nx rats administered everolimus.

Fig. 4. Immunofluorescence analysis for p-mTOR and p-S6. (A–F) Serial sections of Nx rat kidneys are shown. Red signals for p-mTOR (A, C and E) or p-S6 (B, D and F) were merged with green signals for F-actin. (G–J) Effects of everolimus on the expression levels of p-S6 in Nx rats. Red signals for p-S6 were merged with green signals for F-actin and blue signals for DAPI. Symbols (*) represent the localization of glomeruli. Each scale bar represent a length of 100 μm. E(−), Nx rats administered vehicle; E(+), Nx rats administered everolimus.

of p-mTOR and p-S6 was intensified and aggregated in glomeruli (Fig. 4C–F, arrowheads) and the proximal tubular epithelial cells (Fig. 4C–F arrows). However, treatment with everolimus markedly decreased the intensity and area of signals for p-S6 (Fig. 4G–J).

3.2. Effects of everolimus on renal functions in Nx rats

As summarized in Table 1, significant changes in the kidney/body weight ratio, the urinary excretion of albumin (Ualb), and creatinine clearance (Ccr) and an increase in the level of blood urea nitrogen (BUN) were observed with time after renal ablation. When everolimus was administered daily for 14 days beginning at 2 weeks after surgery, significant decreases in Ccr and body weight were observed (Table 1, 4 weeks E(−) vs. E(+)). Although statistically not significant, the level of BUN tended to be increased by the administration of everolimus (Table 1, 4 weeks E(−) vs. E(+)). The kidney/body weight ratio and urinary excretion of albumin were markedly decreased when the administration of everolimus was initiated at 8 weeks after surgery, but the Ccr, level of BUN, body weight and urine volume were not affected by the administration of everolimus (Table 1, 10 weeks E(−) vs. E(+)).

3.3. Renal histology

Fig. 5A–D shows paraffin-embedded sections stained with PAS reagent. The glomerular diameter and inside diameter of tubules increased with time after the surgery (Fig. 5E and F, 4 weeks E(−) vs. 10 weeks E(−)). Glomerular hypertrophy and loss of the brush-border also progressed with time after renal ablation. However, these parameters were significantly decreased by the treatment with everolimus (Fig. 5E and F, 4weeks E(−) vs. E(+), 10 weeks E(−) vs. E(+)).

Strong signals for alpha-SMA and ED1 in the glomeruli (Fig. 6A, C, E and G; arrows) and tubulointerstitial space (Fig. 6A, C, E and G; arrowheads) were observed following Nx. However, the intensity of signals for alpha-SMA and the number of signals for ED1 decreased after the administration of everolimus (Fig. 6B, D, F and H). Furthermore, the expression levels of Kim-1 decreased after the administration of everolimus from 8 weeks after surgery (Fig. 6L), while proximal tubule-specific expression of Kim-1 increased with time after the surgery (Fig. 6I and K). Western blot analysis clearly showed that the expressional changes of alpha-SMA and Kim-1 were comparable with that observed in the immunofluorescence examination (Fig. 6M).

Table 1
Biochemical parameters in Nx rats.

	4 weeks		10 weeks	
	E(−)	E(+)	E(−)	E(+)
Body weight (g)	296 ± 15	242 ± 11*	361 ± 23	333 ± 18
Urine volume (mL/day)	33.1 ± 1.6	37.9 ± 3.5	31.8 ± 2.0	34.5 ± 4.5
Kidney weight/Body weight (%)	0.35 ± 0.03	0.27 ± 0.02	0.47 ± 0.04§	0.32 ± 0.01††
Ccr (mL/min/kg)	3.34 ± 0.51	1.61 ± 0.33*	1.32 ± 0.38§§	0.90 ± 0.29
BUN (mg/dL)	53.9 ± 8.7	111.4 ± 15.0	119.1 ± 31.3	120.7 ± 17.2
Ualb (mg/day)	46.5 ± 15.9	51.1 ± 16.3	128.7 ± 28.8§	45.6 ± 6.7†

Values are the mean ± SEM for six rats. Rats of 4 weeks and 10 weeks represent groups in which a 14-day subcutaneous administration of everolimus (2 mg/kg/day) or vehicle was initiated at 2 and 8 weeks after surgery, respectively. Ccr, creatinine clearance; BUN, blood urea nitrogen; Ualb, urinary albumin excretion; E(−), 5/6 nephrectomized rats administered vehicle; E(+), 5/6 nephrectomized rats administered everolimus. *$P < 0.05$, §$P < 0.05$, §§$P < 0.01$, significantly different from E(−) rats at 4 weeks. †$P < 0.05$, ††$P < 0.01$, significantly different from E(−) rats at 10 weeks.

Fig. 5. Histological analysis of Nx rat kidneys. Four weeks and 10 weeks represent groups in which a 14-day subcutaneous injection was initiated at 2 and 8 weeks after surgery, respectively. (A–D) Representative photographs of PAS staining are shown. (E and F) Glomerular hypertrophy and tubular dilatation were assessed as described in the methods section. E(−), Nx rats administered vehicle; E(+), Nx rats administered everolimus. $^{††}P < 0.01$, $^{*}P < 0.05$, $^{**}P < 0.01$, significantly different.

3.4. Reabsorption of FITC-albumin

Because everolimus significantly decreased the urinary excretion of albumin with minor changes in Ccr and the level of BUN (Table 1), the renal distribution of FITC-albumin was examined to visualize the restored reabsorptive function of proximal tubules (Fig. 7). The urinary FITC-albumin/creatinine ratio was significantly decreased to 31% in the Nx rats by treatment with everolimus from 8 weeks after renal ablation (Fig. 7E). Micrographs revealed green signals for FITC-albumin in the proximal tubules of the cortex where red signals for phalloidin were detected (Fig. 7A–D). In addition, the areas of green signals in the cortex were increased on the administration of everolimus (Fig. 7F), suggesting enhanced reabsorption of albumin from the filtered primary urine. In the kidneys of Nx rats administered vehicle, green signals were predominantly observed close to the brush-border membrane, with relatively weak signals detected at the side of the basolateral membrane (Fig. 7B). However, strong signals for albumin-containing vesicles were distributed throughout the proximal tubular epithelial cells in the everolimus-treated rat kidneys (Fig. 7D).

The treatment with everolimus decreased the number of proximal tubular epithelial cells positive for Kim-1 (Fig. 6), and then, we further analyzed the localization of Kim-1 in FITC-albumin administered rat kidneys (Fig. 7G and H). Immunofluorescence analysis with the antibody specific for Kim-1 showed that the injured proximal tubular epithelial cells, as indicated by red signals for Kim-1, contained little green signals for FITC-albumin (Fig. 7G and H). In contrast, tubular cells that contained strong signals for FITC-albumin were negative for Kim-1 (Fig. 7G and H).

3.5. Protein expression levels of transporters in proximal tubules

To obtain more information about the pharmacological effects of everolimus on tubular functions such as detoxicating systems and ion homeostasis, the protein levels of membrane transporters were examined (Fig. 8). Expression levels of 10 transporter proteins were depressed after surgery. Notably, the levels of NHE3, OCT1, OCT2, OAT1, OAT3, and MATE1 decreased with time after renal ablation. However, the levels of OCT1, OCT2, OAT1, OAT3 and MATE1 in the remnant kidneys after the administration of everolimus from 8 weeks after surgery were much higher than those in rats administered vehicle alone (Fig. 8, 10 weeks E(−) vs. E(+)), while everolimus tended to decrease the levels of OAT1, OAT3 and MATE1 when administered from 2 weeks after renal ablation (Fig. 8, 4 weeks E(−) vs. E(+)). In addition, the treatment with everolimus recovered the protein levels of NHE3 and PEPT2

Fig. 6. Effects of the treatment with everolimus on the progression of CRF. Red signals for alpha-SMA (A–D), ED1 (E–H) and Kim-1 (I–L) in Nx rat kidneys were merged with green signals for F-actin and blue signals for DAPI. (M) Expression levels of alpha-SMA and Kim-1 were confirmed by Western blotting. Symbols (*) represent the localization of glomeruli. Scale bar: 100 μm. E(−), Nx rats administered vehicle; E(+), Nx rats administered everolimus.

independent on the timing of the initiation of treatment (Fig. 8, 4 weeks E(−) vs. E(+), 10 weeks E(−) vs. E(+)). In contrast, everolimus did not affect the levels of SGLT1, PEPT1 and P-gp. The effects of everolimus on the protein levels of membrane transporters, alpha-SMA and Kim-1 were summarized in Fig. 9.

4. Discussion

In the present study, we explored the role of mTOR pathway on the progression of CRF, and revealed the pathological significance of the mTOR pathway in the proximal tubular epithelium in CRF in vivo. Recently, the mTOR pathway has attracted attention for its roles in renal disease. It has been reported to regulate mesangial hypertrophy in diabetic nephropathy [17,18] and cyst formation in polycystic kidney disease [16,29], and to have an important role on the development of compensatory renal hypertrophy after nephron loss [30]. However, the role of the mTOR pathway in the proximal tubules was previously examined only in vitro such as using primary cultured mouse tubular cells [31] and the cultured human proximal tubule cell line, HK2 [32]. There have

been no studies on its role in the progressive tubular dysfunction in CRF in vivo. In the present study, we found that the phosphrylation of Akt, mTOR, S6 kinase and S6 was enhanced in Nx rat kidneys at 4 and 10 weeks after surgery (Fig. 3), and the expression levels of p-mTOR and p-S6 were increased in glomeruli and proximal tubules (Fig. 4). In addition, the daily administration of everolimus for 14 days inhibited the activation of the mTOR pathway as indicated by the levels of p-S6 kinase and p-S6 in association with the signals for p-S6 in the proximal tubules as well as glomeruli (Figs. 3 and 4G–J). Furthermore, the treatment improved the urinary excretion of albumin and renal histology (Table 1, Figs. 5 and 7). These results indicated that the constitutively activated mTOR pathway in proximal tubules plays important roles in the progressive tubular dysfunction as well as glomerular lesions.

The aberrant albuminuria was considered to be due to the decreased reabsorption of albumin at proximal tubules as well as the increased permeability of the glomerular capillary wall [33]. Recently, it was reported that impaired tubular reabsorption of urinary albumin precedes the changes in glomerular permeability of macromolecules in early diabetic nephropathy [34]. In the

Fig. 7. Renal distribution of FITC-albumin. Nx rats 8 weeks after surgery were administered vehicle (E(−); A and B) or everolimus (2 mg/kg/day) (E(+); C and D) for 14 days. FITC-albumin (5 mg/kg) was administered as a bolus via the femoral vein. FITC (green) and F-actin (red) signals were merged in the same section. Urinary concentrations of FITC-albumin (E) and area of signals for FITC in renal cortex (F) were measured. $^{\dagger}P < 0.05$, $^{\dagger\dagger}P < 0.01$, significantly different. FITC (green) signals were merged in the same section with Kim-1 (red) signals (G and H). Scale bar: 100 μm. Symbols (*) represent the localization of glomeruli.

present study, the treatment with everolimus inhibited the progression of albuminuria (Table 1), and this phenomenon was in part due to the increase in its reabsorption at the proximal tubules (Fig. 7A–D and F) rather than the decreased permeability of the glomerular capillary wall without a marked response in

glomerular function to everolimus-treatment (Table 1). On the other hand, it was reported that mTOR inhibition impaired the podocyte's integrity essential as a glomerular filtration barrier for albumin [35]. These findings and backgrounds suggest that everolimus-treatment restores the reabsorbing activity of albumin

Fig. 8. Expression of proximal tubular transporters in the crude plasma membrane fractions of remnant kidneys. Four weeks and 10 weeks represent groups in which a 14-day subcutaneous administration of everolimus (2 mg/kg/day) or vehicle was initiated at 2 and 8 weeks after surgery, respectively. Antisera specific for each transporter (1:1000–10,000 dilution) were used as primary antibodies. Control, membranes obtained from normal kidney; E(−), Nx rats administered vehicle; E(+), Nx rats administered everolimus.

Fig. 9. Effects of everolimus on the protein expression levels of transporters, alpha-SMA and Kim-1. Four weeks (A) and 10 weeks (B) represent groups in which a 14-day subcutaneous administration of everolimus (2 mg/kg/day) or vehicle was initiated at 2 and 8 weeks after surgery, respectively. The densitometric ratio relative to control rat kidneys (for transporters and alpha-SMA) or to the group 4 weeks E(−) (for Kim-1) were shown as the reference. As internal standards, Na$^+$/K$^+$-ATPase alpha1 subunit (for transporters) and beta-actin (for alpha-SMA and Kim-1) were used. Values are the mean ± SEM. E(−), 5/6 nephrectomized rats administered vehicle; E(+), 5/6 nephrectomized rats administered everolimus. $^*P < 0.05$, $^{**}P < 0.01$, significantly different from E(−) rats.

in the proximal tubules, and this pharmacological response is at least a part accountable for the decrease in albuminuria.

We previously found that the tubular secretion of ionic drugs such as *para*-aminohippuric acid and cimetidine was markedly decreased in Nx rats, and a down-regulation of organic ion transporters was responsible for these pharmacokinetic changes [3–6]. Interestingly, everolimus recovered the protein expression of these transporters even in the advanced stage of CRF (Fig. 8). Furthermore, it was revealed that the everolimus-treatment restored the expression levels of NHE3 and PEPT2 (Fig. 8), which play roles in maintaining the pH gradient across the luminal membrane [36] and reabsorption of oligopeptides and peptide mimics [37] in the proximal tubules, respectively. In the kidney, numerous membrane transporters play crucial roles as a detoxicating mechanism in the elimination of organic compounds, such as uremic toxin, into urine via tubular secretion [9,38–40]. Therefore, mTOR inhibition by everolimus in CRF is indicated to be able to bring restoration of tubular functions including the reabsorption of albumin and nutrients, homeostasis in the acid–base balance and detoxication by recovering the membrane transporters in the polarized epithelia.

Although Kim-1 has been characterized as a urinary biomarker of acute kidney injury, little information about its role was clarified in progressive renal failure [41]. In the present study, we have first found that the expression of Kim-1 was induced in the proximal tubules with time after nephrectomy (Fig. 6). The expression of Kim-1 is increased in the injured kidney [23] and is predominantly localized to the apical membrane acting as a receptor for the phagocytosis of apoptotic cells by the proximal tubular epithelium itself [42]. In FITC-albumin-administered rat kidneys, the red signal area with Kim-1 antibody was almost independent from the area of green signals for FITC-albumin (Fig. 7G and H). As expected, the red signal area with Kim-1 antibody was decreased with the increase in the condensed green signals for FITC-albumin in response to the administration of everolimus (Figs. 6 and 7). These results suggested that the inhibition of the mTOR pathway recovered the tubular function coinciding with the amelioration of progressive tubular dysfunction and decrease the expression of Kim-1 in CRF proximal tubules.

Tubular atrophy and interstitial fibrosis are the final common steps on the progression of chronic kidney disease [1]. Epithelial-mesenchymal transition (EMT) is considered to have a crucial role in this pathogenesis [43]. In Nx rats, EMT was observed in the remnant kidney, and alpha-SMA was shown to be a marker for EMT [44,45]. On the other hand, it was reported that the activation of

the mTOR pathway regulate transforming growth factor-beta induced EMT [46] and that the inhibition of mTOR may be effective in intervention for EMT in chronic nephropathies [47]. In this study, treatment with everolimus abolished the accumulation of alpha-SMA in the tubulointerstitial space (Fig. 6). Furthermore, histological analysis revealed that the dilatation of proximal tubules was reduced by the treatment with everolimus (Fig. 5). These results suggest that the constitutively active mTOR pathway modulates dysfunction of proximal tubular epithelial cells via EMT in CRF.

In addition to improving renal tubular functions, everolimus also inhibited the accumulation of alpha-SMA (Fig. 6B and D) and infiltration of macrophages (Fig. 6F and H) without affecting the Ccr or the level of BUN (Table 1) when administration of everolimus was started at 8 weeks after Nx. These results are consistent with the report by Diekmann et al. [19] with another mTOR inhibitor, rapamycin. However, the effects of everolimus were rather complex when the administration was initiated at 2 weeks after renal ablation. Everolimus decreased Ccr and increased the level of BUN, but showed renoprotective effects as indicated by the decreased levels of alpha-SMA and ED1 (Fig. 6) and did not induce further albuminuria (Table 1). Because the hypertrophic responses are predominantly observed within 4 weeks after Nx [38], high doses of mTOR inhibitors could decrease single nephron-GFR and increased both afferent and efferent glomerular resistance without a reduction of whole kidney GFR in normal rat kidney [48]. Therefore, everolimus might cause further reductions of renal function in the rats during the vigorous compensatory adaptation. However, further studies are needed to clarify the discrepancy in the pharmacological response to the inhibition of mTOR after Nx, and the limitation of mTOR inhibitors for CRF focusing on disease stage.

In summary, the constitutive activated mTOR pathway in the proximal tubules was revealed in the rat remnant kidneys. In addition, mTOR inhibitors had renoprotective effects to ameliorate progressive tubular dysfunction in the advanced stage of CRF. Although the precise molecular mechanisms of signal transduction in the progressive renal failure by which the inhibition of mTOR leads to these effects remain to be elucidated, these results suggested an additional therapeutic approach to end-stage renal disease with mTOR inhibitors focusing on the proximal tubular functions.

Acknowledgments

References

[1] Taal MW, Brenner BM. Adaptation to nephron loss. In: Brenner BM, editor. The kidney. WB Saunders; 2008. p. 783–819.

[2] Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448–56.

[3] Takeuchi A, Masuda S, Saito H, Doi T, Inui K. Role of kidney-specific organic anion transporters in the urinary excretion of methotrexate. Kidney Int 2001;60:1058–68.

[4] Ji L, Masuda S, Saito H, Inui K. Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney Int 2002;62:514–24.

[5] Horiba N, Masuda S, Takeuchi A, Saito H, Okuda M, Inui K. Gene expression variance based on random sequencing in rat remnant kidney. Kidney Int 2004;66:29–45.

[6] Nishihara K, Masuda S, Ji L, Katsura T, Inui K. Pharmacokinetic significance of luminal multidrug and toxin extrusion 1 in chronic renal failure rats. Biochem Pharmacol 2007;73:1482–90.

[7] Kwon TH, Frokiaer J, Fernandez-Llama P, Maunsbach AB, Knepper MA, Nielsen S. Altered expression of Na transporters NHE-3, NaPi-II, Na-K-ATPase, BSC-1, and TSC in CRF rat kidneys. Am J Physiol 1999;277:F257–70.

[8] Takahashi K, Masuda S, Nakamura N, Saito H, Futami T, Doi T, et al. Upregulation of H(+)-peptide cotransporter PEPT2 in rat remnant kidney. Am J Physiol Renal Physiol 2001;281:F1109–16.

[9] Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther 2006;109:1–11.

[10] Matsuzaki T, Watanabe H, Yoshitome K, Morisaki T, Hamada A, Nonoguchi H, et al. Downregulation of organic anion transporters in rat kidney under ischemia/reperfusion-induced acute renal failure. Kidney Int 2007;71:539–47.

[11] Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004;23:3151–71.

[12] Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471–84.

[13] Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005;37:19–24.

[14] Stallone G, Infante B, Schena A, Battaglia M, Ditonno P, Loverre A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005;16:3755–62.

[15] Pontrelli P, Rossini M, Infante B, Stallone G, Schena A, Loverre A, et al. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 2008;85:125–34.

[16] Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 2006;103:5466–71.

[17] Nagai K, Matsubara T, Mima A, Sumi E, Kanamori H, Iehara N, et al. Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int 2005;68:552–61.

[18] Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G, et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006;17:1395–404.

[19] Diekmann F, Rovira J, Carreras J, Arellano EM, Banon-Maneus E, Ramirez-Bajo MJ, et al. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol 2007;18:2653–60.

[20] Vogelbacher R, Wittmann S, Braun A, Daniel C, Hugo C. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007;84:1492–9.

[21] Yokomasu A, Yano I, Sato E, Masuda S, Katsura T, Inui K. Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats. Drug Metab Pharmacokinet 2008;23:469–75.

[22] Masuda S, Saito H, Nonoguchi H, Tomita K. Inui K. mRNA distribution and membrane localization of the OAT-K1 organic anion transporter in rat renal tubules. FEBS Lett 1997;407:127–31.

[23] Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998;273:4135–42.

[24] Ogihara H, Saito H, Shin BC, Terado T, Takenoshita S, Nagamachi Y, et al. Immuno-localization of H+/peptide cotransporter in rat digestive tract. Biochem Biophys Res Commun 1996;220:848–52.

[25] Takahashi K, Nakamura N, Terada T, Okano T, Futami T, Saito H, et al. Interaction of beta-lactam antibiotics with H+/peptide cotransporters in rat renal brush-border membranes. J Pharmacol Exp Ther 1998;286:1037–42.

[26] Urakami Y, Okuda M, Masuda S, Saito H, Inui K. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther 1998;287:800–5.

[27] Urakami Y, Nakamura N, Takahashi K, Okuda M, Saito H, Hashimoto Y, et al. Gender differences in expression of organic cation transporter OCT2 in rat kidney. FEBS Lett 1999;461:339–42.

[28] Hashida T, Masuda S, Uemoto S, Saito H, Tanaka K, Inui K. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther 2001;69:308–16.

[29] Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005;16:46–51.

[30] Chen JK, Chen J, Neilson EG, Harris RC. Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J Am Soc Nephrol 2005;16:1384–91.

[31] Andreucci M, Fuiano G, Presta P, Esposito P, Faga T, Bisesti V, et al. Radiocontrast media cause dephosphorylation of Akt and downstream signaling targets in human renal proximal tubular cells. Biochem Pharmacol 2006;72:1334–42.

[32] Mariappan MM, Shetty M, Sataranatarajan K, Choudhury GG, Kasinath BS. Glycogen synthase kinase 3beta is a novel regulator of high glucose- and high insulin-induced extracellular matrix protein synthesis in renal proximal tubular epithelial cells. J Biol Chem 2008;283:30566–75.

[33] Birn H, Christensen EI. Renal albumin absorption in physiology and pathology. Kidney Int 2006;69:440–9.

[34] Russo LM, Sandoval RM, Campos SB, Molitoris BA, Comper WD, Brown D. Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 2009;20:489–94.

[35] Letavernier E, Bruneval P, Vandermeersch S, Perez J, Mandet C, Belair MF, et al. Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 2009;24:630–8.

[36] Boron WF. Acid-base transport by the renal proximal tubule. J Am Soc Nephrol 2006;17:2368–82.

[37] Inui K, Masuda S, Saito H, Cellular. molecular aspects of drug transport in the kidney. Kidney Int 2000;58:944–58.

[38] Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 2002;13:866–74.

[39] Urakami Y, Akazawa M, Saito H, Okuda M. Inui K. cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol 2002;13:1703–10.

[40] Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 2006;17:2127–35.

[41] van Timmeren MM, Bakker SJ, Vaidya VS, Bailly V, Schuurs TA, Damman J, et al. Tubular kidney injury molecule-1 in protein-overload nephropathy. Am J Physiol Renal Physiol 2006;291:F456–64.

[42] Ichimura T, Asseldonk EJ, Humphreys BD, Gunaratnam L, Duffield JS, Bonventre JV. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest 2008;118:1657–68.

[43] Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003;112:1776–84.

[44] Kliem V, Johnson RJ, Alpers CE, Yoshimura A, Couser WG, Koch KM, et al. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 1996;49:666–78.

[45] Ng YY, Huang TP, Yang WC, Chen ZP, Yang AH, Mu W, et al. Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 1998;54:864–76.

[46] Lamouille S, Derynck R. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 2007;178:437–51.

[47] Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, Tang MJ. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 2006;69:2029–36.

[48] Sabbatini M, Sansone G, Uccello F, De Nicola L, Nappi F, Andreucci VE. Acute effects of rapamycin on glomerular dynamics: a micropuncture study in the rat. Transplantation 2000;69:1946–90.